Under the current regulations, healthcare providers are only permitted to import cannabis to fulfill existing cannabis prescriptions, severely limiting their ability to increase market share.
A group of British cannabis companies have called on the UK government to revise the restrictions surrounding the importation and exportation of medical marijuana.
Although medicinal cannabis has been legal in the UK since 2018—following public outrage when news broke that children with epilepsy had been forced to seek treatment abroad—those that work in the industry say that the government's excessive regulation is stalling the sector's growth and pushing investment overseas.
According to the CEO of cannabis distributor Grow Biotech, Ben Langley, the UK may even be in danger of missing out on the growing wave of interest from Canadian and American cannabis investors. Langley claims that Grow Biotech is currently in the process of trying to expand its manufacturing capabilities but has found itself stymied by the government's restrictive regulations.
Read more at thegreenfund.com
